In our case, the close temporal relationship between psychosis and increase in levetiracetam dose and previous reports of levetiracetam-induced psychosis supported our hypothesis of levetiracetam-induced psychosis. Use of the Naranjo Adverse Drug Scale14 also revealed a probable relationship between levetiracetam and psychosis. Also, the rapid resolution of symptoms after decrease in the dose of levetiracetam strengthened our hypothesis. Most likely, in our case, the psychosis as a side effect was a dose-related phenomenon, with psychosis occurring at a dose of 1,500 mg per day and resolving completely at 1,000 mg per day. Various risk factors that could have contributed to psychosis in our case were young age, previous cognitive problems, sensory deprivation, history of seizures, and febrile encephalopathy in the past. The possibility of process of rapid “forced normalization” of the EEG was less possible because of the fact that other drugs achieve rapid normalization of the EEG with no such side effects.15 Other possibilities, such as seizure disorder or postictal psychosis were ruled out on the basis of history and investigations. The mechanism that could explain why some anticonvulsants produce psychosis remains unclear. However, it is possible that the patients who develop such a side effect, may, in fact, have a preexisting psychotic disorder that is not clinically evident. In such cases, the administration of the antiepileptic drug may act as a trigger mechanism. Side effects of levetiracetam include dizziness, fatigue, headache, upper respiratory tract infection, and somnolence. It is well known that levetiracetam can influence behavior. Although there is evidence that the drug may trigger behavioral disorders, there are reports that it may reduce hyperactivity, impulsivity, mood instability, and aggression in autistic children.16 To conclude, there is no doubt that antiepileptic drugs may lead to various psychiatric adverse effects, including psychosis. At present, there is no evidence to suggest that levetiracetam produces psychosis at significantly higher rates than other antiepileptic drugs. Close clinical monitoring with regard to psychiatric adverse effects is needed when starting treatment with antiepileptic drugs. It is especially important in patients with risk factors for psychiatric adverse effects. Further studies to assess the behavioral profile of levetiracetam in large group of patients are needed.